Drug Shortage Report for MYLAN-NAPROXEN/ESOMEPRAZOLE MR

Last updated on 2022-07-08 History
Report ID 152651
Drug Identification Number 02443449
Brand name MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Common or Proper name NAPROXEN/ESOMEPRAZOLE MR
Company Name MYLAN PHARMACEUTICALS ULC
Market Status MARKETED
Active Ingredient(s) ESOMEPRAZOLE NAPROXEN
Strength(s) 20MG 500MG
Dosage form(s) TABLET (IMMEDIATE AND DELAYED-RELEASE)
Route of administration ORAL ORAL
Packaging size 60 BT
ATC code M01AE
ATC description ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS
Reason for shortage Shortage of an active ingredient.
Anticipated start date 2022-03-16
Actual start date 2022-02-18
Estimated end date 2022-06-23
Actual end date 2022-06-22
Shortage status Resolved
Updated date 2022-07-08
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 85 ADVANCE ROAD
ETOBICOKE, ONTARIO
CANADA M8Z 2S6
Company contact information Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2022-01-13 English Compare
v2 2022-01-13 French Compare
v3 2022-01-18 English Compare
v4 2022-01-18 French Compare
v5 2022-01-26 English Compare
v6 2022-01-26 French Compare
v7 2022-02-02 English Compare
v8 2022-02-02 French Compare
v9 2022-02-10 English Compare
v10 2022-02-10 French Compare
v11 2022-02-23 English Compare
v12 2022-02-23 French Compare
v13 2022-03-30 English Compare
v14 2022-03-30 French Compare
v15 2022-05-25 English Compare
v16 2022-05-25 French Compare
v17 2022-06-21 English Compare
v18 2022-06-21 French Compare
v19 2022-07-08 English Compare
v20 2022-07-08 French Compare

Showing 1 to 20 of 20